Regeneron (REGN)
Develops antibody and genetic medicines led by Dupixent, EYLEA HD, and Libtayo.
Something off on this page? Send us feedback.
Discovers and commercializes medicines led by Dupixent for inflammatory disease, EYLEA and EYLEA HD for retinal disease, and Libtayo for cancer. Revenue combines direct product sales with profit shares from Sanofi and Bayer collaborations.
Discovers, develops, manufactures and commercializes medicines for eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, and rare disease. Dupixent anchors inflammation; EYLEA and EYLEA HD anchor retinal care; Libtayo leads oncology. Praluent, Kevzara, Evkeeza, Lynozyfic and Otarmeni extend the commercial portfolio.
Uses human-genetics research and VelociSuite technologies to discover fully human and bispecific antibodies, with most clinical candidates originating in its own laboratories. Revenue combines direct sales and collaboration economics: Sanofi records Dupixent sales worldwide and shares profits, Bayer records EYLEA sales outside the United States, and Libtayo sales are recorded directly worldwide. Regulatory approvals, manufacturing execution and these collaboration agreements remain structural dependencies.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $800 | Target: $920 |
| Aug 17, 2026 | Leerink Partners | Reiterate | Rating: —Target: $641 | Target: $824 |
| Aug 14, 2026 | Bernstein | Reiterate | Rating: —Target: $921 | Target: $756 |
| Aug 3, 2026 | Guggenheim | Reiterate | Rating: —Target: $1,000 | Target: $1,030 |
| Jul 31, 2026 | RBC Capital | Reiterate | Rating: —Target: $707 | Target: $737 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $7.99B · Total debt $1.99B · Total assets $41.73B · Shareholders' equity $31.71B
- Revenue
- $4.29B
- Operating income
- $1.42B
- Net income
- $1.30B
HistoryDividendAnnual yield
| Institutions | 89.62% | 92.27M shares | |
|---|---|---|---|
| 1,392 holders · as of Jun 30, 2026 | |||
| Insiders | 0.79% | 813.9K shares | |
| 20 holders · as of Sep 3, 2026 | |||
| Other | 9.59% | 9.87M shares | |
| remainder | |||
102.95M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.85% | 9.11M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.44% | 6.63M | as of Jun 30, 2026 |
Dodge & CoxInstitution | 4.73% | 4.87M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.70% | 4.83M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 3.83% | 3.94M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Kathryn Guarini | director | −400 | $850.00 |
| Sep 3, 2026 | Marion McCourt | officer: EVP Commercial | −1,131 | $857.39 |
| Sep 2, 2026 | Marion McCourt | officer: EVP Commercial | −1,215 | $850.00 |
| Aug 10, 2026 | Kathryn Guarini | director | −400 | $800.00 |
| Aug 10, 2026 | Huda Y. Zoghbi | director | −800 | $800.00 |
- Sanofi (ADR)
Dupixent partner advancing rival amlitelimab in the same AD space.
- Merck
Keytruda is the PD-1 standard-of-care Libtayo must displace in CSCC and NSCLC.
- AstraZeneca (ADR)
Tezspire and Fasenra challenge Dupixent in the severe asthma market.
- Amgen
Only EYLEA biosimilar on the US market; Tezspire partner; PCSK9 adversary.
- Eli Lilly
Ebglyss (lebrikizumab) directly challenges Dupixent in atopic dermatitis.
- GSK (ADR)
Nucala competes with Dupixent in eosinophilic asthma, CRSwNP, and COPD.
- Bristol-Myers Squibb
Opdivo contests Libtayo in PD-1 NSCLC and non-melanoma skin cancers.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Regeneron | $806.78 | +0.36% | $82.82B | 19.9 | 13.3 | 5.3 | +16.7% |
| Sanofi (ADR) | $41.76 | −1.76% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Merck | $149.80 | −0.74% | $372.73B | 120.7 | 17.4 | 5.6 | +5.1% |
| AstraZeneca (ADR) | $166.78 | −0.94% | $261.12B | 25.3 | 15.7 | 4.3 | +6.4% |
| Amgen | $412.87 | +0.64% | $221.41B | 25.5 | 17.6 | 5.8 | +9.7% |
| Eli Lilly | $1,163.70 | −0.55% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| GSK (ADR) | $50.66 | −0.12% | $101.62B | 16.1 | 9.3 | 2.3 | +5.3% |
| Bristol-Myers Squibb | $61.87 | −0.61% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Median | 25.5 | 16.5 | 4.3 | +6.4% |